Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
03.04.2025 17:42:45

Resolutions from the Annual General Meeting 2025

Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted.

 The following resolutions were made:

  • Approval of the audited Annual Report for 2024
  • Approval of distribution of profit with payment of an ordinary dividend of DKK 4.20 (corresponding to approximately EUR 0.56) per A and B share. In addition to this year-end dividend, an interim dividend of DKK 2.00 (EUR ~0.27) was disbursed on September 3, 2024.
  • Approval of the Remuneration Report for 2024 (advisory vote)
  • Approval of the remuneration of members of the Board of Directors for 2025
  • Re-election of Cornelis (Cees) de Jong as Chair of the Board of Directors
  • Re-election of Heine Dalsgaard as a member of the Board of Directors and election as new Vice Chair
  • Re-election of Lise Kaae, Kasim Kutay, Kevin Lane, Morten Otto Alexander Sommer, and Kim Stratton as members of the Board of Directors
  • Election of Monila Kothari as a new member of the Board of Directors
  • Re-election of EY Godkendt Revisionspartnerselskab as the company’s auditors in respect of statutory financial and sustainability reporting
  • Approval to renew the authorizations to the Board of Directors to implement capital increases
  • Approval to renew the authorization to the Board of Directors to acquire treasury shares
  • Approval of the authorization to the Board of Directors to distribute extraordinary dividends


Composition of the Board of Directors and its committees
After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees.

The Board of Directors, including its committees, is now composed as follows:

  • Cees (Cornelis) de Jong (Chair of the Board, chair of the Nomination and Remuneration Committee and member of the Audit Committee)
  • Heine Dalsgaard (Vice Chair of the Board and member of the Audit Committee)
  • Robert Nøddeskov Jensen (employee representative)
  • Lise Kaae (chair of the Audit Committee)
  • Monila Kothari (member of the Innovation Committee)
  • Kasim Kutay (member of the Nomination and Remuneration Committee)
  • Lars Bo Køppler (employee representative)
  • Kevin Lane (member of the Innovation Committee)
  • Preben Nielsen (employee representative and member of the Innovation Committee)
  • Frederikke Rose Spenner (employee representative)
  • Morten Otto Alexander Sommer (chair of the Innovation Committee)
  • Kim Stratton (member of the Nomination and Remuneration Committee)

For further information on the members of the Board of Directors, please go to www.novonesis.com

Attachment


Analysen zu Novozymes A-S (B)

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

3 Knaller-Aktien im BX Musterportfolio📈: Trane Technologies, Deutsche Boerse & Euronext mit François Bloch

Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ Trane Technologies
✅ Deutsche Boerse
✅ Euronext N.V

Pünktlich zum Börsenstart diskutieren Investment-Stratege François Bloch und Börsen-Experte David Kunz oder Olivia Hähnel über ausgewählte Top-Aktienwerte aus dem BX Musterportfolio.

👉🏽 https://bxplus.ch/bx-musterportfolio/

3 Knaller-Aktien im BX Musterportfolio📈: Trane Technologies, Deutsche Boerse & Euronext mit François Bloch

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 11’550.00 12.93
Short 11’950.00 8.64
SMI-Kurs: 10’887.73 09.04.2025 17:31:15
Long 10’480.18 19.64 3SSMZU
Long 10’220.29 13.54 ARSSMU
Long 9’800.00 8.77
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}